| Similar Articles |
|---|
 |
The Motley Fool
September 15, 2010
Brian Orelli |
Drug Approved. Now Let's Sell This Baby! With ink still wet on its FDA approval, Savient continues its plan to find a buyer.   |
The Motley Fool
August 3, 2009
Brian Orelli |
The Roller-Coaster Stock That Keeps on Giving Savient's gout treatment isn't approved just yet. |
The Motley Fool
May 3, 2007
Mike Havrilla |
Heads Up, Biotech Investors: Chapter 3 Time your stocks, not the market. Savient... VISICU... VIVUS... Cortex... |
The Motley Fool
September 9, 2010
Brian Orelli |
Will These Drugs Get Past the FDA This Month? See what the FDA has on its decision calendar for the rest of September. |
The Motley Fool
December 27, 2010
Brian Orelli |
FDA Kicks Dust on Alimera's Fairy Tale Eight months after its IPO, Alimera gets hammered. |
The Motley Fool
June 17, 2009
Brian Orelli |
Savient Saves and Moves Up The FDA advisory panel gives Savient's Krystexxa a passing grade. |
The Motley Fool
November 10, 2011
Dan Caplinger |
Has Savient Pharmaceuticals Become the Perfect Stock? For Savient to get closer to perfection, it simply has to do one thing: Make Krystexxa the success story it seemed to be last year. |
The Motley Fool
January 25, 2011
Brian Orelli |
FDA Approved -- Now Will It Sell? There's still plenty of uncertainty in Clinical Data's shares. |
BusinessWeek
September 1, 2009
Catherine Arnst |
Opportunities in the Obesity Epidemic Drugmakers are ratcheting up research into treatments for gout and other ills that plague the overweight. |
The Motley Fool
October 25, 2010
Travis Hoium |
Savient Pharmaceuticals Shares Plunged: What You Need to Know Savient Pharmaceuticals shares took a nosedive down 43% on Monday as the company failed to find a buyer for the firm. |
The Motley Fool
January 5, 2012
David Williamson |
Dendreon Investors: Why Shares Are Soaring Tripling Provenge sales causes shares to soar 50%. |
Nurse Practitioner
June 2011
Eva Hardy |
Gout Diagnosis and Management: What NPs Need to Know Because primary care providers diagnose and treat the vast majority of patients with gout, it is important that they understand current guidelines and evidence-based practice. |
The Motley Fool
April 13, 2009
Brian Orelli |
Will These Drugs Get Past the FDA? Hopefully April won't bring showers of tears to these drugmakers: Eli Lilly... AstraZeneca... Bristol-Myers Squibb... Novo Nordisk... Johnson & Johnson... |
The Motley Fool
July 19, 2011
Anand Chokkavelu |
7 Biotechs Near 52-Week Lows Here are the largest seven companies in biotech stocks that are within 20% of their 52-week lows. |
